JP2025503970A5 - - Google Patents

Info

Publication number
JP2025503970A5
JP2025503970A5 JP2024544445A JP2024544445A JP2025503970A5 JP 2025503970 A5 JP2025503970 A5 JP 2025503970A5 JP 2024544445 A JP2024544445 A JP 2024544445A JP 2024544445 A JP2024544445 A JP 2024544445A JP 2025503970 A5 JP2025503970 A5 JP 2025503970A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/011661 external-priority patent/WO2023146991A1/en
Publication of JP2025503970A publication Critical patent/JP2025503970A/ja
Publication of JP2025503970A5 publication Critical patent/JP2025503970A5/ja
Pending legal-status Critical Current

Links

JP2024544445A 2022-01-26 2023-01-26 化合物及び使用方法 Pending JP2025503970A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263303451P 2022-01-26 2022-01-26
US63/303,451 2022-01-26
PCT/US2023/011661 WO2023146991A1 (en) 2022-01-26 2023-01-26 Compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2025503970A JP2025503970A (ja) 2025-02-06
JP2025503970A5 true JP2025503970A5 (https=) 2026-02-16

Family

ID=85328903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544445A Pending JP2025503970A (ja) 2022-01-26 2023-01-26 化合物及び使用方法

Country Status (4)

Country Link
US (1) US20250282749A1 (https=)
EP (1) EP4469445A1 (https=)
JP (1) JP2025503970A (https=)
WO (1) WO2023146991A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CN119731162A (zh) * 2022-08-19 2025-03-28 北京望实智慧科技有限公司 Prmt5抑制剂
CN120476118A (zh) * 2023-01-17 2025-08-12 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
CN120457129A (zh) * 2023-01-31 2025-08-08 四川科伦博泰生物医药股份有限公司 草酸二酰胺化合物、包含其的药物组合物及其制备方法和用途
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
US20250312344A1 (en) * 2024-04-08 2025-10-09 Mirati Therapeutics, Inc. Combination therapies using prmt5 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025217297A1 (en) 2024-04-09 2025-10-16 Tango Therapeutics, Inc. Prmt5 inhibitors for use in methods of treating mta-accumulating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
CA2899363A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
WO2022026892A1 (en) * 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers

Similar Documents

Publication Publication Date Title
JP2025503970A5 (https=)
JP2026031940A (ja) Ｓｈｐ２の活性を阻害するための化合物の製造方法
JP7326622B2 (ja) Ｅｒｋ阻害剤としてのスピロ系化合物およびその使用
KR101960129B1 (ko) 피롤로벤조디아제핀
RU2468021C2 (ru) Гетероциклические соединения и их применение
RU2019133646A (ru) Изохинолины в качестве ингибиторов hpk1
JP2020517616A5 (https=)
JP2025503969A5 (https=)
JP2023518286A5 (https=)
JP2021512059A5 (https=)
IL268030B2 (en) Bicyclics as allosteric shp2 inhibitors
JP2025114615A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
JP2020505376A5 (https=)
RU2015122757A (ru) Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли
RU2006122853A (ru) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
RU2018119173A (ru) Производное бензофурана, способ его получения и его применение в медицине
JP2011527686A5 (https=)
RU2017136715A (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
JP2017506234A5 (https=)
RU2007134396A (ru) Химические соединения
JP2014511840A5 (https=)
JP2020517598A5 (https=)
JP2023519261A5 (https=)
JP2022550353A5 (https=)
JP2020534300A5 (https=)